Comparison of the rates of deamidation, diketopiperazine formation, and oxidation in recombinant human vascular endothelial growth factor and model peptides
- 1 March 2000
- journal article
- research article
- Published by Springer Nature in AAPS PharmSci
- Vol. 2 (1) , 42-47
- https://doi.org/10.1208/ps020105
Abstract
In this work, we examine the way in which stability information obtained from studies on small model peptides correlates with similar information acquired from a protein. The rates of deamidation, oxidation, and diketopiperazine reactions in model peptide systems were compared to those of recombinant human vascular endothelial growth factor (rhVEGF). The N-terminal residues of rhVEGF, a potent mitogen in angiogenesis, are susceptible to the aforementioned reactions. The degradation of the peptides L-Ala-L-Pro-L-Met (APM) and Gly-L-Gsn-L-His-L-His (GQNHH), residues 1–3 and 8–12 of rh VEGF, respectively, and rhVEGF were examined at pH 5 and 8 at 37°C. Capillary electrophoresis and high-performance liquid chromatography (HPLC) stability-indicating assays were developed to monitor the degradation of the penta- and tripeptides, respectively. The degradation of rhVEGF was determined by tryptic mapping and quantified by RP-HPLC. The rates of degradation of both peptides and the protein followed apparent first-order kinetics and increased with increasing pH. The tripeptide APM underwent diketopiperazine formation (Ala-Prodiketopiperazine) and oxidation of the Met residue, whereas the pentapeptide GQNHH degraded via the deamidation pathway. The results indicate that the rates of deamidation and oxidation of the protein are comparable to those observed in the model peptides at both pH values. However, the rate of the diketo-piperazine reaction was slower in the protein than in the model peptide, which may be the result of differences in the cis-trans equilibrium of the X-Pro peptide bonds in the 2 molecules.Keywords
This publication has 18 references indexed in Scilit:
- Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsPublished by Elsevier ,2004
- Kinetics of Diketopiperazine Formation Using Model PeptidesJournal of Pharmaceutical Sciences, 1998
- The Carboxyl-terminal Domain(111–165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic PotencyJournal of Biological Chemistry, 1996
- VEGF121, a Vascular Endothelial Growth Factor (VEGF) Isoform Lacking Heparin Binding Ability, Requires Cell-surface Heparan Sulfates for Efficient Binding to the VEGF Receptors of Human Melanoma CellsJournal of Biological Chemistry, 1995
- Mechanism of Enzymatic and Nonenzymatic Prolyl Cis-Trans IsomerizationAdvances in Protein Chemistry, 1993
- The vascular endothelial growth factor family of polypeptidesJournal of Cellular Biochemistry, 1991
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989
- Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells.Proceedings of the National Academy of Sciences, 1989
- Effect of proline residues on protein foldingJournal of Molecular Biology, 1981
- An explanation for the rare occurrence of cis peptide units in proteins and polypeptidesJournal of Molecular Biology, 1976